Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial
Eastell, R × Lang, T Boonen, Sofie Cummings, S Delmas, P D Cauley, J A Horowitz, Z Kerzberg, E Bianchi, G Kendler, D Leung, P Man, Z Mesenbrink, P Eriksen, E F Black, D M HORIZON Pivotal Fracture Trial #
Osteoporosis International vol:21 issue:7 pages:1277-85
Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength.